The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo

Theranostics in Japan

Author(s): Seigo Kinuya *

Pp: 221-231 (11)

DOI: 10.2174/9781681088655122010020

* (Excluding Mailing and Handling)


Frankly, Japan is at the end of the line of current clinical theranostics such as
PRRT and PSMA. Many patients go abroad for PRRT and PSMA treatment. This
lamentable situation has been caused mainly by the strict regulations as well as the
limited number of isolation rooms available for these purposes in this country. But
despite this, Japanese scientists are developing several unique activities in theranostics,
including 211At[NaAt] for 131I radioiodine refractory thyroid cancer and meta-211Atastato-
benzyl guanidine (211At-MABG) for 131I-MIBG refractory pheochromocytoma/
paraganglioma, which are currently ready for investigator-initiated trial. There are
several other developments in this field. Such information is described in this short

Keywords: 131I-MIBG, 211At[NaAt], 225Ac-fibroblast activation protein inhibitor (FAPI), 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), Mmeta-211At-astato-benzylguanidine (211At-MABG).

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy